Recombinant Human His6-A20/TNFAIP3 Catalytic Domain, CF
Recombinant Human His6-A20/TNFAIP3 Catalytic Domain, CF Summary
Product Specifications
Contains an N-terminal 6-His tag
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
E-344
| Formulation | X mg/ml (X μM) in 50 mM MOPS pH 6.5, 150 mM NaCl, 0.5 mM EDTA, 10% Glycerol (v/v), 1 mM DTT |
| Shipping | The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Reconstitution Calculator
Background: A20/TNFAIP3
A20, also known as TNF-alpha -induced Protein 3 (TNFAIP3) is a 790 amino acid (aa) cytoplasmic protein with a predicted molecular weight of 90 kDa. It was originally described as a protein upregulated by TNF-alpha stimulation (1). Human A20/TNFAIP3 exhibits 88% aa sequence identity to its mouse ortholog. Structurally, it contains seven zinc finger domains, one of which has Ubiquitin ligase (E3) activity. The N-terminus contains a deubiquitinating enzyme (DUB) domain. As such, A20/TNFAIP3 can be classified as a dual function Ubiquitin editing enzyme. It is known for its ability to modulate inflammatory immune responses by acting as a negative feedback regulator of NF kappa B signaling (2,3). Some putative mechanisms include its ability to modulate upstream components of the NF kappa B pathway such as RIP1, TRAF2, and TRAF6 (4-6). Deficiencies in A20/TNFAIP3 have been associated with lymphoid malignancies, and the development of inflammatory and autoimmune disorders (7,8).
This A20/TNFAIP3 catalytic domain includes aa residues 1-371 and an N-terminal his.
- Opipari, A.W. Jr. et al. (1992) J. Biol. Chem. 267:12424.
- Jaattela, M. et al. (1996) J. Immunol. 156:1166.
- Song, H.Y. et al. (1996) Proc. Natl. Acad. Sci. USA 93:6721.
- Wertz, I.E. et al. (2004) Nature 430:694.
- Boone, D.L. et al. (2004) Nat. Immunol. 5:1052.
- Shembade, N. et al. (2010) Science 327:1135.
- Zhang, F. et al. (2012) Cancer Cell Int. 12:44.
- Harhag, E.W. & V.M. Dixit (2012) Immunol. Rev. 246:107.
Citation for Recombinant Human His6-A20/TNFAIP3 Catalytic Domain, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
-
Identification Of Small Molecule TRABID Deubiquitinase Inhibitors By Computation-Based Virtual Screen.
Authors: Shi T, Bao J, Wang N, Zheng J, Wu D
BMC Chem Biol, 2012-05-14;12(1):4.
Applications: Bioassay
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human His6-A20/TNFAIP3 Catalytic Domain, CF
There are currently no reviews for this product. Be the first to review Recombinant Human His6-A20/TNFAIP3 Catalytic Domain, CF and earn rewards!
Have you used Recombinant Human His6-A20/TNFAIP3 Catalytic Domain, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
